Cargando…
Plasma lipoproteome in Alzheimer’s disease: a proof-of-concept study
BACKGROUND: Although total plasma lipoproteome consists of proteins that have shown promises as biomarkers that can identify Alzheimer’s disease (AD), effect sizes are modest. The objective of this study is to provide initial proof-of-concept that the plasma lipoproteome more likely differ between A...
Autores principales: | Li, Danni, Huang, Fangying, Zhao, Yingchun, Villata, Peter W., Griffin, Timothy J., Zhang, Lin, Li, Ling, Yu, Fang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6147047/ https://www.ncbi.nlm.nih.gov/pubmed/30250409 http://dx.doi.org/10.1186/s12014-018-9207-z |
Ejemplares similares
-
Lipoproteome screening of the Lyme disease agent identifies inhibitors of antibody-mediated complement killing
por: Pereira, Michael J., et al.
Publicado: (2022) -
Serum NMR Profiling Reveals Differential Alterations in the Lipoproteome Induced by Pfizer-BioNTech Vaccine in COVID-19 Recovered Subjects and Naïve Subjects
por: Ghini, Veronica, et al.
Publicado: (2022) -
Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease
por: Voss, Tiffini, et al.
Publicado: (2018) -
Plasma Neurofilament Light and Future Declines in Cognition and Function in Alzheimer’s Disease in the FIT-AD Trial
por: Li, Danni, et al.
Publicado: (2021) -
Proof of concept in cardiovascular risk: the paradoxical findings in blood pressure and lipid abnormalities
por: Fuchs, Flavio Danni, et al.
Publicado: (2012)